Hyperphagia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hyperphagia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety of Carbetocin Nasal Spray for Treating Uncontrollable Hunger in Patients with Prader-Willi Syndrome https://clinicaltrials.eu/trial/study-on-the-safety-of-carbetocin-nasal-spray-for-treating-uncontrollable-hunger-in-patients-with-prader-willi-syndrome/ Wed, 29 Apr 2026 15:03:26 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-carbetocin-nasal-spray-for-treating-uncontrollable-hunger-in-patients-with-prader-willi-syndrome/ This clinical trial is focused on studying a condition called Prader-Willi Syndrome (PWS), which is a genetic disorder that can cause a constant feeling of hunger, known as hyperphagia. The trial is testing a treatment using a medication called Carbetocin Nasal Spray, which is an oxytocin-like chemical designed to help manage this uncontrollable hunger.

The purpose of the study is to learn about the safety of using Carbetocin Nasal Spray over a long period. Participants in the study will use the nasal spray, which is administered through the nose, to see if it helps reduce the symptoms of hyperphagia. The study will monitor participants for any side effects or changes in their condition while using the spray.

Throughout the study, participants will have regular check-ups to assess their response to the treatment. These check-ups will include questionnaires and evaluations to track changes in their hunger levels and overall well-being. The study aims to provide valuable information on how safe and effective Carbetocin Nasal Spray is for people with Prader-Willi Syndrome.

]]> Study on Carbetocin Nasal Spray for Reducing Uncontrollable Hunger in Patients with Prader-Willi Syndrome https://clinicaltrials.eu/trial/study-on-carbetocin-nasal-spray-for-reducing-uncontrollable-hunger-in-patients-with-prader-willi-syndrome/ Wed, 29 Apr 2026 14:29:00 +0000 https://clinicaltrials.eu/trial/study-on-carbetocin-nasal-spray-for-reducing-uncontrollable-hunger-in-patients-with-prader-willi-syndrome/ This clinical trial is focused on studying a condition called Prader-Willi Syndrome (PWS), which is a genetic disorder that can cause a strong, uncontrollable hunger known as hyperphagia. The trial is testing a new treatment called Carbetocin Nasal Spray, which is a nasal spray solution designed to help reduce this excessive hunger. The study will compare the effects of the Carbetocin Nasal Spray, also known by its code name ACP-101, to a placebo, which is a substance with no active medication.

The purpose of the study is to see how effective the Carbetocin Nasal Spray is in managing hyperphagia in people with Prader-Willi Syndrome. Participants in the study will be randomly assigned to receive either the Carbetocin Nasal Spray or the placebo. The study will last for a period of 12 weeks, during which participants will use the nasal spray and attend regular study visits to monitor their progress. The nasal spray is administered through the nose using a special device called the Aptar CPS Nasal Spray Pump.

Throughout the study, researchers will assess changes in the participants’ hunger levels and overall condition using specific questionnaires and clinical evaluations. The goal is to determine if the Carbetocin Nasal Spray can significantly reduce the symptoms of hyperphagia in individuals with Prader-Willi Syndrome compared to those receiving the placebo. This study aims to provide valuable insights into a potential new treatment option for managing this challenging aspect of Prader-Willi Syndrome.

]]>